Revive Therapeutics Doubles Bought Deal Financing To $20.0 Million
Revive Therapeutics (CSE: RVV) has upsized the bought deal financing announced last night. Originally pegged at $10.0 million in gross
Read more
Revive Therapeutics
Revive Therapeutics Conducts $10.0 Million Bought Deal Financing
Revive Therapeutics (CSE: RVV) this evening announced that it will be conducting a bought deal financing, lead by Leede Jones
Read more
Revive Therapeutics Announces Research Collaboration For Natural Psilocybin Biosynthesis
Revive Therapeutics (CSE: RVV) this morning announced that it has entered into a sponsored research collaboration agreement, as well as
Read more
Revive Therapeutics Appoints Airway Disease Expert As Advisor For COVID-19 Phase 3 Study
Revive Therapeutics (CSE: RVV) has strengthened its scientific and advisory team as it looks to close out the year. Dr
Read more
Revive Therapeutics Continues With Phase 3 Clinical Trial For Bucillamine, To File For Emergency Use Authorization
Revive Therapeutics (CSE: RVV) issued an update to the market this morning related to its phase 3 clinical trial for
Read more
Revive Therapeutics Enters LOI To Acquire Psilocybin Program From PharmaTher
Revive Therapeutics (CSE: RVV) this morning announced that it has entered into a letter of intent to acquire PharmaTher Inc’s
Read more
Growing Medical Acceptance of Psychedelics – The Daily Dive feat Derek Welsh of Revive Therapeutics
For our final episode of The Daily Dive this week, host Cassandra Leah is joined by that of Derek Welsh
Read more
Revive Therapeutics, Pharmather Partner On Psilocybin Cancer Research
Revive Therapeutics (CSE: RVV) and Pharmather Inc (CSE: PHRM) this morning jointly announced a research collaboration between the two firms.
Read more
Revive Therapeutics Completes Psilocybin Oral Thin Film Strip Product
Revive Therapeutics (CSE: RVV) has completed its oral thin film strip product for psilocybin after several months of prototyping. The
Read more
Revive Expects To Complete Phase 3 Interim Analysis In December On Bucillamine In Treatment of COVID-19
Revive Therapeutics (CSE: RVV) provided an update on the status of its ongoing phase three clinical trials for the evaluation
Read more